Andrea Tan
Stock Analyst at Goldman Sachs
(1.63)
# 3,324
Out of 5,182 analysts
47
Total ratings
39.02%
Success rate
-2.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrea Tan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $206 → $327 | $272.52 | +19.99% | 2 | Feb 2, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Neutral | $50 → $85 | $73.91 | +15.00% | 3 | Jan 7, 2026 | |
| INSM Insmed | Maintains: Buy | $258 → $225 | $135.17 | +66.46% | 15 | Dec 18, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $16 → $8 | $3.44 | +132.56% | 7 | May 12, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Neutral | $46 → $51 | $61.45 | -17.01% | 4 | May 5, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Neutral | $23 → $6 | $5.86 | +2.39% | 5 | Jul 1, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Sell | $3 → $2 | $7.21 | -72.26% | 3 | Jun 5, 2024 | |
| KOD Kodiak Sciences | Reinstates: Sell | $2 | $44.84 | -95.54% | 1 | Dec 11, 2023 | |
| ABCL AbCellera Biologics | Maintains: Buy | $27 → $24 | $4.15 | +478.31% | 2 | Aug 4, 2023 | |
| FATE Fate Therapeutics | Maintains: Sell | $10 → $4 | $1.33 | +200.75% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $375 | $512.39 | -26.81% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $80 | $13.81 | +479.29% | 2 | May 24, 2022 |
Krystal Biotech
Feb 2, 2026
Maintains: Buy
Price Target: $206 → $327
Current: $272.52
Upside: +19.99%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Neutral
Price Target: $50 → $85
Current: $73.91
Upside: +15.00%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $258 → $225
Current: $135.17
Upside: +66.46%
Iovance Biotherapeutics
May 12, 2025
Maintains: Buy
Price Target: $16 → $8
Current: $3.44
Upside: +132.56%
Tarsus Pharmaceuticals
May 5, 2025
Maintains: Neutral
Price Target: $46 → $51
Current: $61.45
Upside: -17.01%
Sagimet Biosciences
Jul 1, 2024
Maintains: Neutral
Price Target: $23 → $6
Current: $5.86
Upside: +2.39%
Relmada Therapeutics
Jun 5, 2024
Downgrades: Sell
Price Target: $3 → $2
Current: $7.21
Upside: -72.26%
Kodiak Sciences
Dec 11, 2023
Reinstates: Sell
Price Target: $2
Current: $44.84
Upside: -95.54%
AbCellera Biologics
Aug 4, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $4.15
Upside: +478.31%
Fate Therapeutics
Jan 9, 2023
Maintains: Sell
Price Target: $10 → $4
Current: $1.33
Upside: +200.75%
Dec 20, 2022
Maintains: Buy
Price Target: $178 → $375
Current: $512.39
Upside: -26.81%
May 24, 2022
Maintains: Neutral
Price Target: $120 → $80
Current: $13.81
Upside: +479.29%